Lansoprazole is a proton pump inhibitor that accumulates in gastric parietal cell canaliculi, where it is protonated and converted to a sulfenamide intermediate. This reactive metabolite covalently binds cysteine residues on the H+/K+-ATPase, irreversibly blocking acid secretion until new pumps are synthesized.